Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) patients (pts) who have failed brentuximab vedotin (BV) have a poor prognosis with a median OS after BV failure of 2.9 months and 2-year OS of 27.1% (Chihara D, 2019). ALK-inhibitors have shown interesting results in relapsed ALK+ ALCL, but in these studies, most pts had not received prior BV, which does not correspond to current standards of treatment in adults.
Introduction: The RELEVANCE randomized trial showed that the combination of lenalidomide + rituximab (R2) has similar efficacy to rituximab + chemotherapy (R-chemo) in patients (pts) with advanced-stage, previously untreated follicular lymphoma (FL) after 6 years of follow-up. In this study, using RNA sequencing we identify high-risk patients benefiting from R2. Methods: RNAseq on FFPE biopsies was performed for 324 enrolled pts (grade 1–2 and 3A) at diagnosis.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
